[Dipeptidyl peptidase IV in inflammatory bowel diseases (DPP IV/CD26)]

Arh Hig Rada Toksikol. 2012 Mar;63(1):75-100. doi: 10.2478/10004-1254-63-2012-2185.
[Article in Croatian]

Abstract

Inflammatory bowel diseases (Crohn's disease, ulcerative colitis, undetermined colitis) are a group of chronic autoimmune inflammatory diseases distinguished by recurrent inflammation of various parts of the gastrointestinal (GI) system and presenting a significant public health problem. Despite large basic and clinical research, the aetiology of these diseases and the pathogenesis of inflammation itself remain elusive. Previous studies have confirmed a causal relationship between mediators of inflammatory response and molecules involved in the regulation of their biological activity, especially proteases. The aim of this review is to summarise earlier findings on different aspects of inflammatory bowel diseases, paying particular attention to the involvement of dipeptidyl peptidase IV (CD26 molecule, DPP IV/CD26) in the etiopathogenesis of inflammatory processes in the GI tract. Animal studies of colitis have significantly contributed to the understanding and treatment of these diseases, investigations of ulcerative colitis (DSS-colitis) and Crohn's disease (TNBS-colitis) on the murine model in particular.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Animals
  • Dipeptidyl Peptidase 4 / physiology*
  • Humans
  • Inflammatory Bowel Diseases / enzymology*
  • Inflammatory Bowel Diseases / etiology
  • Risk Factors

Substances

  • Dipeptidyl Peptidase 4